Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
-
-
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
-
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend…
-
Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
-
Broad Institute expanded COVID-19 viral sequencing efforts for variant surveillance in the Northeast
On Apr. 9, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
-
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
-
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyﾒs COVID-19…
-
Biotechnology | CDC | COVID-19 | Infectious Disease | NIH | Vaccine
CDC awarded $3 billion to expand COVID-19 vaccine programs
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it has awarded funding to support…
-
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial is underway to determine…
-
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
-
AIM ImmunoTech announced positive data in phase 1 study Investigating intranasal administration of Ampligen as potential treatment for COVID-19
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…
-
COVID-19 | Implants | Infectious Disease | NIH | Vaccine
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
-
Nearly 80 percent of teachers, school staff, and childcare workers received at least one shot of COVID-19 vaccine
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
-
Moderna and Catalent announced long-term strategic collaboration for vial filling of COVID-19 vaccine
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
-
The FDA issued an EUA to Symbiotica for the COVID-19 self-collected antibody test system
On Apr. 5, 2021, the FDA issued an Emergency Use Authorization (EUA) to Symbiotica for the COVID-19 Self-Collected…
-
Positive phase 1/2 results reported for Valneva’s inactivated COVID-19 vaccine candidate using CpG 1018ﾙ adjuvant
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
-
Innovation Pharma announced increased dosing in phase 2 clinical trial of Brilacidin in COVID-19 patients
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…
-
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
-
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
-
Emergent announced topline data from NIAID phase 3 ITAC Trial evaluating immunoglobulins as treatment for patients with COVID-19
On Apr. 2, 2021, Emergent BioSolutions announced that topline data from the ITAC trial had demonstrated that the…
-
FDA revised Moderna COVID-19 vaccine EUA to increase the number of vaccine doses available
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…
-
Moderna provided storage update and FDA authorization for 15-doses per vial of COVID-19 vaccine
On Apr. 1, 2021, Moderna announced that based on submitted stability data, the U.S. Food and Drug Administration…
-
Pfizer and BioNTech confirmed high efficacy and no serious safety concerns in updated COVID-19 vaccine study
On Apr. 1, 2021, Pfizer and BioNTech announced updated topline results from analysis of 927 confirmed symptomatic cases…
-
Arbutus Biopharma, X-Chem and Proteros biostructures entered into pan-coronavirus discovery research and license agreement
On Apr. 1, 2021, Arbutus Biopharma, X-Chem and Proteros Biostructures announced hat they had entered into a discovery…
-
Biotechnology | COVID-19 | Diagnostics | FDA
Quidel’s QuickVue At-Home OTC COVID-19 Test received EUA for screening use with serial testing
On Mar. 31, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the U.S….
-
Pfizer-BioNTech announced positive topline results of pivotal COVID-19 vaccine study in adolescents
On Mar. 31, 2021, Pfizer and BioNTech announced that, in a Phase 3 trial in adolescents 12 to…
-
T cells recognize recent SARS-CoV-2 variants
On Mar. 30, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that researchers had analyzed…
-
OraSure Technologies submitted COVID-19 rapid antigen prescription home self-test to FDA for EUA
On Mar. 30, 2021, OraSure Technologies announced that it had submitted an application to the U.S. Food and…
-
Qx Therapeutics received FDA authorization with IND for QXT-101 in phase 2 trial for patients with COVID-19 infection.
On Mar. 30, 2021, Qx Therapeutics announced that the FDA had cleared the company’s Investigational New Drug application…
-
CytoDyn’s leronlimab decreased mortality at 14 days by 82% amongst critically Ill COVID-19 patients
On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19….
